Could outperform Wegovy and cagrisema: Novo Nordisk starts trial with obesity hope
Novo Nordisk expects the candidate amycretin to provide at least the same weight loss as cagrisema, the successor to Wegovy, says the company’s head of development.
With the initiation of a new phase I trial, Novo Nordisk has named the pharmaceutical company’s next big hope in the treatment of obesity, and according to the company’s head of development, Martin Holst Lange, the expectations for the potential obesity drug are already high.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
